Director, Regulatory Affairs, Cellectis
Dr. Bartido completed her doctoral studies at New York University working on an alternative Class II processing and presentation pathway of a viral antigen. She holds a PhD in Immunology and an MBA in Pharmaceutical Management. Her postdoctoral work at Memorial Sloan Kettering Cancer Center involved the development of DNA vaccines using the melanocytic antigen tyrosinase for the treatment of melanoma. Following her postdoctoral work, she joined the Carl Icahn Institute of Gene Therapy and Molecular Medicine as an Assistant Professor to serve as the Assistant Director of the Gene Therapy Immunology Core Laboratory. In this role, she developed several immunomonitoring tools for assaying efficacy of adenoviral directed immunotherapies targeting metastatic liver cancer. This was followed by an 11-year role as the Senior Quality Manager of the MSKCC Cell Therapy and Cell Engineering Facility. In this role, she developed the QA program for the development and GMP manufacturing of autologous CD19 Chimeric Antigen Receptor T cell therapies targeting several indications in leukemia and prostate cancer as well as gene therapy for the treatment of B-Thalassemia using lentiviral transduced CD34+ HPSCs. She was integral to the design and construction of a state of the art GMP facility at MSKCC. Presently, she is the Director of Regulatory Affairs at Cellectis Inc. The company is presently involved in the development of allogeneic CAR T cells as a universal off the shelf immunotherapy for leukemias.